Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Licensing revenue, contract revenue and deferred revenue (Details)

v3.19.3.a.u2
Licensing revenue, contract revenue and deferred revenue (Details)
$ in Thousands, $ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Dec. 31, 2018
USD ($)
Dec. 31, 2018
CAD ($)
Dec. 31, 2010
USD ($)
Disclosure of joint ventures [line items]        
Licensing revenue $ 318 $ 118    
Deferred revenue (note 10) 206 324    
3SBio        
Disclosure of joint ventures [line items]        
Licensing revenue 118 118    
License fee income       $ 1,500
Deferred revenue (note 10) 324 442    
MAH        
Disclosure of joint ventures [line items]        
Licensing revenue 200      
MAH | VOS        
Disclosure of joint ventures [line items]        
Licensing revenue $ 200      
Contravir Pharmaceuticals, Inc.        
Disclosure of joint ventures [line items]        
Revenue from contracts with customers   $ 345 $ 450